Heart Disease News and Research

Latest Heart Disease News and Research

Health literacy leads to less hospitalization for heart failure

Being able to read and understand words like anemia, hormones and seizure means a patient with heart failure may be less likely to be hospitalized, according to a new study from Emory University School of Medicine. Findings will be presented Nov. 17 at the American Heart Association Scientific Sessions conference in Chicago.

18 Nov 2010

Children with severe congenital heart defects show high risk of emotional reactivity

Research from the Norwegian Institute of Public Health (NIPH) shows that children with severe congenital heart defects have twice the risk of anxiety at 18 months of age compared to healthy children. Children with mild and moderate heart defects, on the other hand, did not show an increased risk of anxiety.

18 Nov 2010

PAREXEL reaches milestone in early phase studies

PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced that it reached a milestone of completing 200 early phase studies in patient populations during the past three years.

From Parexel 18 Nov 2010

Study finds sfrp2 protein may play a role in accelerating heart muscle repair

Heart tissue and stem cells spring into action to begin repairing muscle damaged in a heart attack, and researchers at Duke University School of Medicine found that a protein naturally produced in the body may potentially play a role in accelerating heart muscle repair.

18 Nov 2010

Back pain sufferers get quicker diagnosis and treatment when examined by Nurse Practitioner

Results of a Toronto Western Hospital study show that patients suffering back pain get quicker diagnosis and treatment when a Nurse Practitioner conducts the first examination. Traditionally, patients face long and anxiety-ridden wait times - up to 52 weeks - before an initial examination by a spine surgeon. Results from the year long TWH study showed wait times for patients examined by a Nurse Practitioner were significantly shorter, ranging from 10 to 21 weeks.

18 Nov 2010

Gene transfer reduces and stabilizes plaque and decreases inflammation

A plaque-fighting gene - studied in various forms by researchers at the Cedars-Sinai Heart Institute for 18 years - has now been transferred intravenously to lab mice bred to model atherosclerosis (clogged arteries) in humans. Studies show the gene transfer reduced and stabilized plaque and decreased inflammation, key factors in cutting the risk of heart disease.

18 Nov 2010

MEDRAD to offer RSNA attendees hands-on demonstration on P3T PA software

MEDRAD will offer RSNA attendees hands-on demonstrations of personalized-protocol software that individualizes CT Pulmonary Angiography (CTPA) contrast dosing, and has proven to increase the percentage of diagnostic-quality studies to rule out Pulmonary Embolism (PE) when compared to the institution's standard protocol potentially obviating the need to rescan the patient.

18 Nov 2010

CDC data: Adults remain unvaccinated against preventable infectious illnesses

New data from the Centers for Disease Control and Prevention (CDC) show that adults remain largely unvaccinated against preventable infectious illnesses.

18 Nov 2010

Study finds Hispanic children are susceptible to develop fatty liver disease

Two studies from the Childhood Obesity Research Center at the Keck School of Medicine of the University of Southern California (USC) have found evidence that Hispanic children and adolescents are genetically predisposed to developing fatty liver disease a condition that can lead to cirrhosis, cardiovascular disease and diabetes.

18 Nov 2010

Sun Pharma receives FDA approval for generic Tiazac ANDA

Sun Pharmaceutical Industries Ltd. announced that USFDA has granted its subsidiary an approval for its Abbreviated New Drug Application (ANDA) to market a generic version of once-a-day Tiazac® extended release capsules.

18 Nov 2010

FDA approves Sun Pharma's generic Clarinex ANDA

Sun Pharmaceutical Industries Ltd. announced that USFDA has granted it an approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Schering Plough's Clarinex® tablets, 5 mg.

18 Nov 2010

LVNC cardiomyopathy associated with heart failure, stroke and ventricular arrhythmias

Left ventricular non-compaction (LVNC), a cardiomyopathy about which little is fully understood, is associated with heart failure (HF), stroke and ventricular arrhythmias, according to a study to be presented Nov. 17 at the 2010 American Heart Association (AHA) Scientific Sessions in Chicago. The researchers also will report that advanced imaging technologies reveal that developing these cardiac risks appear to progress over time in patients with LVNC.

18 Nov 2010

Researchers report results from Phase III DEFINE study for coronary heart disease

Researchers today presented results from the Phase III DEFINE (Determining the EFficacy and Tolerability of CETP INhibition with AnacEtrapib) study with Merck's investigational CETP inhibitor, anacetrapib. In the trial of 1,623 patients with coronary heart disease (CHD) or CHD risk equivalents, anacetrapib showed no significant differences from placebo in the primary safety measures studied.

18 Nov 2010

CARMAT completes assembly of first artificial heart clinical version

CARMAT, the designer and developer of the world's most advanced artificial heart, today announced that it has completed the assembly of the first clinical version of its artificial heart (to be implanted in humans during clinical trials scheduled for 2011).

18 Nov 2010

Cardiac stem cells from sick patients could generate new heart muscle: Research

Cardiac stem cells even in elderly and sick patients could generate new heart muscle and vessel tissue and be used to treat heart failure, according to research presented at the American Heart Association's Scientific Sessions 2010.

18 Nov 2010

Children's heart disease affects mental health of mothers

Mothers of children with severe heart disease are more likely to suffer from anxiety and depression than mothers of healthy children, even once any medical interventions are over.

18 Nov 2010

Report plus Great American Smokeout offer reasons to quit, renew tobacco prevention efforts

A new report issued by Blue Cross and Blue Shield of Minnesota (Blue Cross) shows that each year, smoking is responsible for 5,135 deaths in Minnesota and $2.87 billion in excess medical costs to treat diseases caused by smoking. The report, titled "Health Care Costs and Smoking in Minnesota," was completed by Jeffrey Fellows, Ph.D., and a nationally known health economist from the Center for Health Research at Kaiser Permanente Northwest.

18 Nov 2010

Merck announces FDA Advisory Committee approval of GARDASIL for anal cancer and AIN treatment

Merck announced today that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee has advised that the data presented support an indication for GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] for the prevention of anal cancer and anal intraepithelial neoplasia (AIN) in both males and females 9 through 26 years of age.

18 Nov 2010

miR765 RNA may play a role in development of heart failure: Research

Researchers at the University of Cincinnati (UC) have found a potential genetic target for heart disease, which could lead to therapies to prevent the development of the nation's No. 1 killer in its initial stages.

18 Nov 2010

European study on fat stem cells could help treat heart attack

Emerging Healthcare Solutions, Inc. anticipates the results of a new European study on treating heart attacks with stem cells taken from patients' belly fat.

18 Nov 2010